Foundation Medicine and Sarah Cannon Collaborate to Advance Personalized Medicine for Patients with Cancer
Molecular Information-based Collaboration Focuses on Integrating Comprehensive Genomic Profiling into Clinical Trials to Enable Patient Access to Targeted Therapeutics
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161031005386/en/
Sarah Cannon is one of the world's leading clinical research organizations conducting community-based clinical trials across a global network. Researchers can use Foundation Medicine's CGP assays, FoundationOne® for use with solid tumors, FoundationOne® Heme for use with hematologic malignancies and FoundationACT™ for use as a liquid biopsy, to identify eligible patients for participation in Sarah Cannon's clinical studies. Foundation Medicine's CGP assays aid treating physicians and researchers to more effectively screen and match patients to early and late-phase clinical trials based on their genomic information. Sarah Cannon will also integrate Interactive Cancer Explorer®, Foundation Medicine's physician facing decision support portal, across its network to facilitate clinico-genomic knowledge among researchers and to enhance patient access to precision therapeutics.
Additionally, Sarah Cannon and
"Our physicians are at the forefront of clinical research through our work with novel investigative therapies," said Howard A. "Skip" Burris, M.D., president, clinical operations and chief medical officer, Sarah Cannon. "Clinical trials, particularly those where patients can be molecularly matched to a study, are an integral part of effectively treating many types of cancers and accelerating patient access to novel therapies. We're excited to collaborate with
Sarah Cannon and
"Precision medicine in cancer can be achieved by innovating new ideas that accelerate patient access to novel compounds in development," said
About
About
Cautionary Note Regarding Forward-Looking Statements for
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the implementation of the collaboration between
View source version on businesswire.com: http://www.businesswire.com/news/home/20161031005386/en/
For
Media Contact:
dan@purecommunicationsinc.com
or
Investor Contact:
kbrown@foundationmedicine.com
or
For Sarah Cannon:
Gabrielle.hannafan@sarahcannon.com
Source:
News Provided by Acquire Media